Attend our event to explore effective strategies to gain competitive advantage and understand the role of safety biomarkers in clinical development.
Leading Pharma companies will share first hand experience with adaptive trial designs and case studies on optimizing trial development in order to speed approval time and improve operational efficiency. This two days debate and pioneering case-studies will be focused on topics such as:
- Breast Cancer Clinical Trials in Developing Countries with Ismail Jatoi, University of Texas Health Science Center, USA, Dale H. Dorn Chair in Surgery, Professor and Chief, Division of Surgical Oncology, Department of Surgery
- Biomarker-driven drug development in Oncology challenges that change paradigms with Miro Venturi, Roche, Germany, Senior Biomarker & Experimental Medicine Leader
- Are we Efficient in Drug Development? With Yasser Mostafa Kamel, GlaxoSmithKline, UK, Senior Clinical Development Director Oncology
- Clinical Trials in Rare Diseases with Nicolas Leupin, Celgene, Switzerland, Director, Clinical Research & Development EMEA
- and many more.